Gracias por escuchar. Estas son los artículos a los que se hace referencia en este episodio del podcast:

Ogdie, A. et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann. Rheum. Dis. 74, 326–332 (2014).

Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J. & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoidarthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 71, 1524–1529 (2012).

Schieir, O., Tosevski, C., Glazier, R. H., Hogg-Johnson, S.& Badley, E. M. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann. Rheum. Dis. 76, 1396–1404 (2017). 21.

D’Agostino, R. B. et al. General cardiovascular risk profile for use in primary care. Circulation 117, 743–753 (2008).

Arts, E. E. A. et al. Performance of four current risk 23. algorithms in predicting cardiovascular events inpatients with early rheumatoid arthritis. Ann. Rheum.Dis. 74, 668–674 (2015). 24.

Crowson, C. S., Matteson, E. L., Roger, V. L., Therneau, T. M. & Gabriel, S. E. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am. J. Cardiol. 110, 420–424 (2012). 25.

Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms ofinflammatory joint disorders: 2015/2016 update. 26. Ann. Rheum. Dis. 76, 17–28 (2017).

Gómez-Vaquero, C. et al. SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis 27. Res. Ther. 15, R91 (2013).

Ahlehoff, O. et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J. Intern. Med. 270, 147–157 (2011).

Polachek, A., Touma, Z., Anderson, M. & Eder, L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res. 69, 67–74 (2017).

Gulati, A. M. et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann. Rheum. Dis. 75, 819–824 (2016).

Eder, L., Wu, Y., Chandran, V., Cook, R. & Gladman, D. D. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann. Rheum. Dis. 75, 1680–1686 (2016).

Eder, L. et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study.J. Rheumatol. 45, 378–384 (2018).

Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973–979 (1997).

Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).

Sever, P. S. et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo- Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J. Am. Coll. Cardiol. 62, 717–729 (2013).

Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019).

Szentpetery, A. et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol. 70, 396–407 (2018).

Min, J. K. et al. Relationship of coronary artery plaque composition to coronary artery stenosis severity: results from the prospective multicenter ACCURACY trial. Atherosclerosis 219, 573–578 (2011).